Company: PACB
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001299130-25-000102
Chunk: 161

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 161
---
 financial statements. 

Q1 Fiscal 2025 Form 10-Q4

Table of Contents

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(Unaudited)

Three Months Ended March 31, 2025Common StockAdditional Paid-inCapitalAccumulatedOtherComprehensive IncomeAccumulated DeficitTotalStockholders'Equity(In thousands)SharesAmountBalance at December 31, 2024294,418$294 $2,654,804 $422 $(2,148,926)$506,594 Net loss—— — — (426,075)(426,075)Other comprehensive loss—— — (41)— (41)Issuance of common stock in conjunction with equity plans5,6236 1,953 — — 1,959 Share-based compensation expense—— 9,201 — — 9,201 Balance at March 31, 2025300,041$300 $2,665,958 $381 $(2,575,001)$91,638 

Three Months Ended March 31, 2024Common StockAdditional Paid-inCapitalAccumulatedOtherComprehensive Income (Loss)Accumulated DeficitTotalStockholders'Equity(In thousands)SharesAmountBalance at December 31, 2023267,744$268 $2,539,892 $219 $(1,839,075)$701,304 Net loss—— — — (78,178)(78,178)Other comprehensive loss—— — (525)— (525)Issuance of common stock in conjunction with equity plans4,5364 6,887 — — 6,891 Share-based compensation expense—— 19,525 — — 19,525 Balance at March 31, 2024272,280$272 $2,566,304 $(306)$(1,917,253)$649,017 

See accompanying notes to the condensed consolidated financial statements.

Q1 Fiscal 2025 Form 10-Q5

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) Three Months Ended March 31,(In thousands)20252024Cash flows from operating activitiesNet loss$(426